voltage dependent anion channel 1 pseudogene 4Genealiases: VDAC4 · VDAC4P
Q-omics provides the consensus-scored VDAC1P4 profile across patient tissues and cancer cell-line models. VDAC1P4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, VDAC1P4 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, VDAC1P4 RNA expression shows 13,587 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, LIHC, and LSCC as cancer lineages where VDAC1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VDAC1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VDAC1P4 survival associations across molecular data types. VDAC1P4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VDAC1P4 RNA expression–survival associations across cancer types. High VDAC1P4 expression shows unfavorable associations in BLCA, ACC, STAD and UCEC, but favorable associations in READ and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for VDAC1P4 RNA expression.
This table summarizes VDAC1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for VDAC1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VDAC1P4 shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA, LUSC, LUAD and CHOL. The LIHC box plot shows higher VDAC1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .019).
This table shows molecular features associated with VDAC1P4 in patient tissues and cancer cell lines. In patient samples, VDAC1P4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
